p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101
- 13 February 2001
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (4) , 1859-1864
- https://doi.org/10.1073/pnas.98.4.1859
Abstract
Functional inactivation of the tumor susceptibility gene tsg101 in NIH 3T3 fibroblasts results in cellular transformation and the ability to form metastatic tumors in nude mice. The N-terminal region of tsg101 protein is structurally similar to the catalytic domain of ubiquitin-conjugating enzymes, suggesting a potential role of tsg101 in ubiquitin-mediated protein degradation. The C-terminal domain of TSG101 can function as a repressor of transcription. To investigate the physiological function of tsg101 , we generated a null mutation of the mouse gene by gene targeting. Homozygous tsg101 −/− embryos fail to develop past day 6.5 of embryogenesis (E6.5), are reduced in size, and do not form mesoderm. Mutant embryos show a decrease in cellular proliferation in vivo and in vitro but no increase in apoptosis. Although levels of p53 transcripts were not affected in tsg101 −/− embryos, p53 protein accumulated dramatically, implying altered posttranscriptional control of p53. In addition, transcription of the p53 effector, cyclin-dependent kinase inhibitor p21 WAF-1/CIP-1 , was increased 5- to 10-fold, whereas activation of MDM2 transcription secondary to p53 elevation was not observed. Introduction of a p53 null mutation into tsg101 −/− embryos rescued the gastrulation defect and prolonged survival until E8.5. These results demonstrate that tsg101 is essential for the proliferative burst before the onset of gastrulation and establish a functional connection between tsg101 and the p53 pathway in vivo .Keywords
This publication has 32 references indexed in Scilit:
- Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: Common types of shorter transcripts are true alternative splice variantsOncogene, 1998
- A Putative Tumor Suppressor, TSG101, Acts as a Transcriptional Suppressor through Its Coiled-Coil DomainBiochemical and Biophysical Research Communications, 1998
- TSG101 may be the prototype of a class of dominant negative ubiquitin regulatorsNature Genetics, 1997
- Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancerNature Genetics, 1997
- Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutationNature Genetics, 1997
- Transgenic mice with p53-responsive lacZ: p53activity varies dramatically during normal development and determines radiation and drug sensitivity invivoThe EMBO Journal, 1997
- RETRACTED: The TSG101 Tumor Susceptibility Gene Is Located in Chromosome 11 Band p15 and Is Mutated in Human Breast CancerCell, 1997
- The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the MouseCell, 1996
- Tumor spectrum analysis in p53-mutant miceCurrent Biology, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993